Filter the drugs by their COVID-19 status ,phase of research and how they help

COVID-19 is a respiratory disease caused by the SARS-CoV-2 virus. Browse the database of potential drugs for COVID-19 treatment compiled by the AIM tool.
Substance COVID-19 status Phase of research How it helps Latest publication
Casirivimab
RNA
Emergency use authorization Experimental Antiviral Jan/23/2023
Imdevimab
RNA
Emergency use authorization Experimental Antiviral Jan/23/2023
Mesenchymal stem cells
RNA
Potential treatment - clinical evidence Experimental Other treatment Oct/17/2022
Bamlanivimab
RNA
Potential treatment - clinical evidence Experimental Antiviral Jun/23/2022
Etesevimab
RNA
Potential treatment - clinical evidence Experimental Antiviral Jun/23/2022
S309
RNA
Potential treatment - pre-clinical evidence Experimental Antiviral Jun/22/2022
Ad26.COV2.S
RNA
Emergency use authorization Experimental Vaccine Jun/22/2022
BNT162b2
RNA
Approved by FDA Experimental Vaccine Jun/22/2022
mRNA-1273
RNA
Emergency use authorization Experimental Vaccine Jun/22/2022
Cilgavimab
RNA
Emergency use authorization Experimental Antiviral Jun/18/2022
Tixagevimab
RNA
Emergency use authorization Experimental Antiviral Jun/18/2022
REGEN-COV
RNA
Emergency use authorization Experimental Antiviral Jun/03/2022
Convalescent plasma
RNA
Emergency use authorization Experimental Antiviral May/16/2022
ACE2‐Fc
RNA
Potential treatment - pre-clinical evidence Experimental Antiviral Apr/26/2022
mAb 222
RNA
Potential treatment - pre-clinical evidence Experimental Antiviral Jan/04/2022
mAb Beta-55
RNA
Potential treatment - pre-clinical evidence Experimental Antiviral Jan/04/2022
mAb Beta-29
RNA
Potential treatment - pre-clinical evidence Experimental Antiviral Jan/04/2022
mAb 58
RNA
Potential treatment - pre-clinical evidence Experimental Antiviral Jan/04/2022
mAb Beta-54
RNA
Potential treatment - pre-clinical evidence Experimental Antiviral Jan/04/2022
mAb 253
RNA
Potential treatment - pre-clinical evidence Experimental Antiviral Jan/04/2022